Biomea Fusion Inc
NASDAQ:BMEA
Biomea Fusion Inc
Total Equity
Biomea Fusion Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomea Fusion Inc
NASDAQ:BMEA
|
Total Equity
$51.6m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
-$2.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$21.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$9.6B
|
CAGR 3-Years
38%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$17.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
16%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$31.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
23%
|
CAGR 10-Years
24%
|
|
Biomea Fusion Inc
Glance View
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California and currently employs 51 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The firm has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical irreversible programs for the treatment of select cancers.
See Also
What is Biomea Fusion Inc's Total Equity?
Total Equity
51.6m
USD
Based on the financial report for Dec 31, 2024, Biomea Fusion Inc's Total Equity amounts to 51.6m USD.
What is Biomea Fusion Inc's Total Equity growth rate?
Total Equity CAGR 3Y
-34%
Over the last year, the Total Equity growth was -70%. The average annual Total Equity growth rates for Biomea Fusion Inc have been -34% over the past three years .
